Hardik Modi

762 total citations
17 papers, 588 citations indexed

About

Hardik Modi is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Hardik Modi has authored 17 papers receiving a total of 588 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Hematology, 8 papers in Genetics and 4 papers in Molecular Biology. Recurrent topics in Hardik Modi's work include Chronic Myeloid Leukemia Treatments (12 papers), Chronic Lymphocytic Leukemia Research (8 papers) and Acute Lymphoblastic Leukemia research (3 papers). Hardik Modi is often cited by papers focused on Chronic Myeloid Leukemia Treatments (12 papers), Chronic Lymphocytic Leukemia Research (8 papers) and Acute Lymphoblastic Leukemia research (3 papers). Hardik Modi collaborates with scholars based in United States, United Kingdom and Germany. Hardik Modi's co-authors include Ravi Bhatia, Stephen J. Forman, Wenyong Chen, Zhiqiang Wang, David Horne, Hao Zhang, Ling Li, Hongfeng Yuan, Tessa L. Holyoake and Tinisha McDonald and has published in prestigious journals such as Blood, Cancer Research and British Journal of Haematology.

In The Last Decade

Hardik Modi

15 papers receiving 582 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hardik Modi United States 10 351 223 222 98 86 17 588
Sarah Swerdlow United States 5 189 0.5× 172 0.8× 110 0.5× 60 0.6× 36 0.4× 10 386
Christian Hurtz United States 10 258 0.7× 246 1.1× 107 0.5× 32 0.3× 151 1.8× 32 607
Soumen Chakraborty India 13 197 0.6× 434 1.9× 60 0.3× 38 0.4× 88 1.0× 27 635
Daniel P. Sejas United States 10 146 0.4× 475 2.1× 48 0.2× 15 0.2× 85 1.0× 10 641
Giuseppe Di Lernia Italy 6 84 0.2× 189 0.8× 47 0.2× 42 0.4× 53 0.6× 6 397
Ashwini Yenamandra United States 9 100 0.3× 363 1.6× 46 0.2× 18 0.2× 37 0.4× 21 523
Babu Rao Vundinti India 13 180 0.5× 219 1.0× 106 0.5× 36 0.4× 27 0.3× 50 406
Jessie J.F. Medeiros Canada 5 269 0.8× 233 1.0× 68 0.3× 17 0.2× 70 0.8× 7 429
Kimihito C. Kawabata Japan 9 291 0.8× 323 1.4× 123 0.6× 10 0.1× 95 1.1× 18 529
Kim-Hien T. Dao United States 10 303 0.9× 309 1.4× 190 0.9× 80 0.8× 50 0.6× 13 566

Countries citing papers authored by Hardik Modi

Since Specialization
Citations

This map shows the geographic impact of Hardik Modi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hardik Modi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hardik Modi more than expected).

Fields of papers citing papers by Hardik Modi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hardik Modi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hardik Modi. The network helps show where Hardik Modi may publish in the future.

Co-authorship network of co-authors of Hardik Modi

This figure shows the co-authorship network connecting the top 25 collaborators of Hardik Modi. A scholar is included among the top collaborators of Hardik Modi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hardik Modi. Hardik Modi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Sidana, Surbhi, Christof Scheid, Petra Schuberth, et al.. (2024). Global Manufacturing Experience with Idecabtagene Vicleucel in Patients with Relapsed and Refractory Multiple Myeloma. Blood. 144(Supplement 1). 3476–3476.
2.
Modi, Dimpy, Saifur Rahman Chowdhury, Hardik Modi, et al.. (2024). Primary versus Secondary Immune Thrombocytopenia (ITP): A Meeting Report from the 2023 McMaster ITP Summit. Thrombosis and Haemostasis. 125(9). 923–932. 1 indexed citations
3.
Narla, Rama Krishna, Hardik Modi, Daniel E. Bauer, et al.. (2021). Modulation of CD47-SIRPα innate immune checkpoint axis with Fc-function detuned anti-CD47 therapeutic antibody. Cancer Immunology Immunotherapy. 71(2). 473–489. 29 indexed citations
4.
Modi, Hardik, et al.. (2017). Literary review article on efficacy of Guduchi in diabetic peripheral neuropathy. International journal of applied research. 3(2). 200–203.
5.
Narla, Rama Krishna, Hardik Modi, Lilly Wong, et al.. (2017). Abstract 4694: The humanized anti-CD47 monclonal antibody, CC-90002, has antitumor activity in vitro and in vivo. Cancer Research. 77(13_Supplement). 4694–4694. 13 indexed citations
6.
Schemionek, Mirle, Hans‐Ulrich Klein, Sylwia Flis, et al.. (2013). Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells. Blood. 121(20). 4175–4183. 82 indexed citations
7.
8.
Yuan, Hongfeng, Zhiqiang Wang, Ling Li, et al.. (2011). Activation of stress response gene SIRT1 by BCR-ABL promotes leukemogenesis. Blood. 119(8). 1904–1914. 145 indexed citations
9.
10.
Helgason, G. Vignir, Ashley Hamilton, Svetlana Myssina, et al.. (2010). Is Bcr-Abl expression relevant for the survival of cancer stem cells in chronic myeloid leukaemia (CML)?. British Journal of Haematology. 149. 72–72. 1 indexed citations
11.
Samanta, Abhishek, Sharmistha Chakraborty, Xiaolin Sun, et al.. (2010). Janus kinase 2 regulates Bcr–Abl signaling in chronic myeloid leukemia. Leukemia. 25(3). 463–472. 73 indexed citations
12.
Modi, Hardik, Lushen Li, S. Haihua Chu, et al.. (2010). Inhibition of Grb2 expression demonstrates an important role in BCR–ABL-mediated MAPK activation and transformation of primary human hematopoietic cells. Leukemia. 25(2). 305–312. 41 indexed citations
13.
König, Helmut, Melissa Holtz, Hardik Modi, et al.. (2008). Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors. Leukemia. 22(4). 748–755. 87 indexed citations
14.
Myssina, Svetlana, G. Vignir Helgason, Alan Serrels, et al.. (2008). Combined BCR-ABL inhibition with lentiviral-delivered shRNA and dasatinib augments induction of apoptosis in Philadelphia-positive cells. Experimental Hematology. 37(2). 206–214. 3 indexed citations
15.
Modi, Hardik, Tinisha McDonald, Su Chu, et al.. (2007). Role of BCR/ABL gene-expression levels in determining the phenotype and imatinib sensitivity of transformed human hematopoietic cells. Blood. 109(12). 5411–5421. 49 indexed citations
16.
17.
König, Helmut, Melissa Holtz, Hardik Modi, et al.. (2006). Nilotinib Inhibits Bcr-Abl Kinase Activity in CML Progenitor Cells More Effectively Than Imatinib but Is Equipotent in Inducing Growth Inhibition.. Blood. 108(11). 744–744. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sarah Swerdlow Breakdown of academic impact, for papers by Christian Hurtz Breakdown of academic impact, for papers by Soumen Chakraborty Breakdown of academic impact, for papers by Daniel P. Sejas Breakdown of academic impact, for papers by Giuseppe Di Lernia Breakdown of academic impact, for papers by Ashwini Yenamandra Breakdown of academic impact, for papers by Babu Rao Vundinti Breakdown of academic impact, for papers by Jessie J.F. Medeiros Breakdown of academic impact, for papers by Kimihito C. Kawabata Breakdown of academic impact, for papers by Kim-Hien T. Dao
Rankless by CCL
2026